The injectable drug delivery market to grow from USD 362.4 billion in 2016 to USD 624.5 billion by 2021, at a Compound Annual Growth Rate (CAGR) of 11.5% during the forecast period.
The major factors responsible for the growth of this market are the increasing use of biologics, increase in the prevalence of chronic diseases, increasing occurrence of needlestick injuries, and the benefits of injections (convenience, ease of use, and reduced pain). These factors have increased the demand for devices such as safety syringes, prefilled syringes, and autoinjectors.
The objective of the report is to define, describe, and forecast the injectable drug delivery market size based on type, formulation packaging, therapeutic application, usage pattern, site of administration, distribution channel, facility of use, and region.
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=150
By therapeutic applications, the market is segmented into autoimmune diseases, hormonal disorders, cancer, orphan diseases, and other therapeutic applications (pain management, allergies, hepatitis C, aesthetic treatment, and hemophilia). Cancer segment is expected to register the highest CAGR during the forecast period.
Based on formulation packaging, the market is segmented into the ampules, vials, cartridges, and bottles. Ampules are expected to dominate the Injectable drug delivery market, in 2016. The large share of this market segment can be attributed majorly due to its good barrier properties as compared to other types of packaging; moreover, they offer better protection at a lower cost. Ease of transportation and low cost of manufacturing are the factors driving the growth in this segment.
Geographical Growth Scenario:
Based on region, the injectable drug delivery market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is further subsegmented into the U.S. and Canada; while Europe is further subsegmented into Germany, France, the U.K., Italy, Spain, and the Rest of Europe (RoE); Asia is further subsegmented into Japan, China, India, and the Rest of Asia (RoA).
Along with this, the rise in disposable income, the growing awareness of safety and comfort, and the increasing number of partnerships in this market space are also contributing to the growth. In 2016, North America is expected to dominate the market, followed by Europe. The large share of North America is attributed to the increasing prevalence of chronic diseases and the number of companies that are focused on collaboration and partnerships to ensure the availability of high-value products.
Asia is projected to be the fastest-growing region in the injectable drug delivery market from 2016 to 2021, due to the rising incidence of chronic diseases and the growing aging population. Moreover, high penetration of self-injection technologies in Asian countries such as China, Japan, and India adds to the demand for injectable devices.
Key Players:
Prominent players in the injectable drug delivery market include Becton, Dickinson and Company (U.S.), Baxter International (U.S.), Pfizer (U.S.), Gerresheimer AG (Germany), Schott AG (Germany), Eli Lilly and Company (U.S.), and Terumo Corporation (Japan).
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=150
